EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [21] CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care
    Hui, Rina
    de Boer, Richard
    Lim, Elgene
    Yeo, Belinda
    Lynch, Jodi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 3 - 14
  • [22] Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study
    Dent, S.
    Alder, L.
    Broadwater, G.
    Hyslop, T.
    Oeffinger, K.
    Khouri, M.
    Balu, S.
    Kimmick, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S505 - S506
  • [23] Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2- metastatic breast cancer treated with a CDK4/6i in the first-line setting (vol 31, pg 6, 2025)
    Behan, E.
    Veenstra, D. L.
    Bansal, A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (02): : 226 - 226
  • [24] OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2-advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors
    Sohn, Joohyuk
    Pistilli, Barbara
    Bellet, Meritxell
    Del Mastro, Lucia
    McArthur, Heather L.
    Meisel, Jane Lowe
    Schmid, Peter
    Wei, Rachel
    Chan, Arlene
    de Kermadec, Elisabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS22 - TPS22
  • [25] OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2-advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors
    Pistilli, Barbara
    Bellet, Meritxell
    Del Mastro, Lucia
    McArthur, Heather L.
    Meisel, Jane Lowe
    Schmid, Peter
    Sohn, Joohyuk
    De Kermadec, Elisabeth
    Wei, Rachel
    Chan, Arlene
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
    Galardi, F.
    Biagioni, C.
    De Luca, F.
    Curigliano, G.
    Minisini, A. M.
    Bonechi, M.
    Moretti, E.
    Risi, E.
    Migliaccio, I.
    McCartney, A.
    Benelli, M.
    Romagnoli, D.
    Conti, V.
    Biganzoli, L.
    Di Leo, A.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S18 - S18
  • [27] A phase Ib trial of fulvestrant+CDK4/6 inhibitor (CDK4/6i) palbociclib plus pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ER+/HER2-negative metastatic breast cancer (MBC)
    Mayer, Ingrid A.
    Haley, Barbara B.
    Abramson, Vandana G.
    Brufsky, Adam
    Rexer, Brent
    Stringer-Reasor, Erica
    Jhaveri, Komal L.
    Sanders, Melinda
    Ericsson-Gonzalez, Paula I.
    Ye, Fei
    Arteaga, Carlos L.
    CANCER RESEARCH, 2021, 81 (04)
  • [28] Clinical algorithm to predict who may benefit from CDK4/6 inhibitors in patients (p) with estrogen receptor positive and HER-2 negative (ER+/Her2-) metastatic breast cancer (MBC).
    Felip-Falgas, Eudald
    Teruel, Iris
    Garcia Mosquera, Juan Jose
    Erasun, Carlos
    Quiroga Garcia, Vanesa
    Angelats, Laura
    Espana, Sofia
    Cucurull, Marc
    Cirauqui, Beatriz
    Margeli Vila, Mireia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER22 recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor
    Kogawa, Takahiro
    Yamashita, Toshinari
    Ishida, Takanori
    Yonemori, Kan
    Iwata, Hiroji
    Shimomura, Akihiko
    Aogi, Kenjiro
    Inoue, Kenichi
    Mukohara, Toru
    Nakayama, Takahiro
    Sakai, Hitomi
    Kitano, Shigehisa
    Kobayashi, Shingo
    Nakada, Takuya
    Suzuki, Ippei
    Otake, Yohei
    Tsurutani, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] OPERA-01: A randomized, open-label, phase 3, study of palazestrant (OP-1250) vs standard-of- care treatment for ER+, HER2-advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy
    Chan, Arlene
    Meisel, Jane
    Jhaveri, Komal
    Sohn, Joo Hyuk
    Bellet-Ezquerra, Meritxell
    Schroeder, Jason
    Shilkrut, Mark
    Pistilli, Barbara
    CANCER RESEARCH, 2024, 84 (09)
12345